Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RT_28-15 | Other Identifier | Instituto Antártico Chileno |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fuerza Aérea de Chile | OTHER_GOV |
| Instituto Antártico Chileno | UNKNOWN |
| Harvard Medical School (HMS and HSDM) | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate vitamin D (VD) deficiency in the population of Chilean Antarctica and evaluate the efficacy and safety of VD supplementation to decrease VD deficiency and favorably influence biomarkers for bone, cardiovascular, and immune health risk in the inhabitants of Chilean Antarctica.
The present study consists of an initial cross-sectional evaluation of VD status and specific health biomarkers in inhabitants of Chilean Antarctica, followed by a randomized controlled trial evaluating two acceptable approaches of vitamin D supplementation (cholecalciferol 600 IU daily vs. 25000 IU weekly) in Antarctic inhabitants.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard daily vitamin D3 | Active Comparator | Cholecalciferol 600 IU daily during one year or exit from Antarctica. |
|
| Higher weekly vitamin D3 | Active Comparator | Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cholecalciferol | Dietary Supplement | Administration of vitamin D3 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in serum 25-hydroxyvitamin D concentration | In Antarctic inhabitants not supplemented with VD that exit Antarctica before start of RCT phase of study. | at end of Antarctic residency or 1 year (90-365 days), whichever came first |
| Measure | Description | Time Frame |
|---|---|---|
| sun exposure | questionnaires | at 0, 6, 12 months of Antarctic residency |
| sleep pattern | questionnaires | at 0, 6, 12 months of Antarctic residency |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arturo Borzutzky, M.D. | School of Medicine, Pontificia Universidad Católica de Chile | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014808 | Vitamin D Deficiency |
| ID | Term |
|---|---|
| D001361 | Avitaminosis |
| D003677 | Deficiency Diseases |
| D044342 | Malnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D002762 | Cholecalciferol |
| ID | Term |
|---|---|
| D002782 | Cholestenes |
| D002776 | Cholestanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| food intake of VD | Food frequency questionnaire | at 0, 6, 12 months of Antarctic residency |
| serum biomarkers for bone metabolism | intact PTH, calcium phosphorus, alkaline phosphatases, VD-binding protein | at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first |
| serum high-sensitivity C-reactive protein (hsCRP) | at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first |
| serum cathelicidin (LL-37) concentration | at baseline and every 3 months during supplementation (3,6,9,12 months) up to end of Antarctic residency or 1 year (90-365 days), whichever came first |
| D009750 |
| Nutritional and Metabolic Diseases |
| D011083 |
| Polycyclic Compounds |
| D013261 | Sterols |
| D014807 | Vitamin D |
| D012632 | Secosteroids |
| D008563 | Membrane Lipids |
| D008055 | Lipids |